Ovarian Cancer Drug Could Expand-Use for Other Cancer Types

The drug lynparza (Olaparib), which is approved for the treatment of ovarian cancer with BRCA mutations, has the potential to treat a broader range of cancer types, a recent study suggests.

The metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair DNA, causing tumors to become desensitized to lynparza therapy.

In a study published in the Journal of Cell Biology, investigators found that a PGAM1 inhibitor may help boost the efficacy of lynparza by re-sensitizing the tumors to treatment.

In order to synthesize the materials that cancer cells require for rapid growth, they often alter their metabolic pathway. PGAM1 regulates multiple metabolic pathways, and there are abnormally high levels of this enzyme in cancers, such as breast cancer, lung cancer, and prostate cancer.

For the study, the investigators injected mice with human breast cancer cells containing functional BRCA1 and BRCA2 genes to form tumors. When lynparza was used alone, it had no efficacy on the tumors. However, when lynparza was combined with a PGAM1 inhibitor, it impaired both homologous recombination and PARP-dependent DNA repair, resulting in a significant suppression of tumor growth.

When PGAM1 was inhibited, the cancerous cells synthesized fewer deoxyribonucleotide triphosphates (dNTPs), which are the building blocks of DNA, according to the authors.

“This suggest that PGAM1 inhibitors can sensitive cancers to PARP inhibitors such as [lynparza], thereby expanding the benefits of PARP inhibitors to BRCA1/2-proficient cancers, particularly triple-negative breast cancers that currently lack effective therapies,” said author Min Huang.
 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

FDA grants nivolumab (Opdivo) its seventh priority review designation.
Approximately 10% of the HIV population will die from lung cancer.
Patients undergoing chemotherapy can use Emend with other antiemetic medicines to prevent chemotherapy-related nausea and vomiting.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2017
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.